{"organizations": [], "uuid": "6f0629fa9bd66535688da9bc381018160d1c040e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180115.html", "section_title": "Archive News &amp; Video for Monday, 15 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-hebei-changshan-biochemical-pharma/brief-hebei-changshan-biochemical-pharmaceutical-sees-fy-2017-net-profit-up-10-pct-to-30-pct-idUSL3N1PA2PV", "country": "US", "domain_rank": 408, "title": "BRIEF-Hebei Changshan Biochemical Pharmaceutical sees FY 2017 net profit up 10 pct to 30 pct", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.963, "site_type": "news", "published": "2018-01-15T15:21:00.000+02:00", "replies_count": 0, "uuid": "6f0629fa9bd66535688da9bc381018160d1c040e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-hebei-changshan-biochemical-pharma/brief-hebei-changshan-biochemical-pharmaceutical-sees-fy-2017-net-profit-up-10-pct-to-30-pct-idUSL3N1PA2PV", "ord_in_thread": 0, "title": "BRIEF-Hebei Changshan Biochemical Pharmaceutical sees FY 2017 net profit up 10 pct to 30 pct", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-hebei changshan biochemical pharmaceutical", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "hebei changshan biochemical pharmaceutical co ltd", "sentiment": "negative"}, {"name": "beijing headline news", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 15(Reuters) - Hebei Changshan Biochemical Pharmaceutical Co Ltd :\n* Sees FY 2017 net profit to increase by 10 percent to 30 percent, or to be 193.0 million yuan to 228.1 million yuan\n* Says FY 2016 net profit was 175.5 million yuan\n* The reasons for the forecast are increased sales price of raw heparin and improved product sales Source text in Chinese: goo.gl/ZivUj1 Further company coverage: (Beijing Headline News)\n ", "external_links": ["https://goo.gl/ZivUj1", "http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-15T15:21:00.000+02:00", "crawled": "2018-01-16T13:34:13.009+02:00", "highlightTitle": ""}